FIT Biotech to study further the feasibility of its GTU®-technology in gene therapy – FIT Biotech

Reports and Releases

FIT Biotech to study further the feasibility of its GTU®-technology in gene therapy

FIT Biotech Oy

Company Announcement, September 29, 2015 at 11.00 am EET

FIT Biotech to study further the feasibility of its GTU®-technology in gene therapy

Biotechnology company FIT Biotech Oy announced in May 2015 positive results related to applying its platform technology for gene therapy. The company has continued preclinical studies as planned in order to demonstrate proof-of-concept of the GTU®-technology in gene therapy.

The new positive results further confirm feasibility of the technology. The duration of effect has proven longer than anticipated and it has been decided to add more time points in order to document the overall length of the effect.

The first studies were designed to measure the effect by using marker proteins indicating proof of technology. The new preclinical study aims at demonstrating clinical utility of the technology in expressing a monoclonal antibody that is in clinical use.

The new study is expected to be completed during first half of 2016.

Gene therapy is a new and rapidly developing medical research field utilizing transfer of genes into human somatic cells to induce desired therapeutic or preventive effects by coding the cells to produce certain proteins.

FIT BIOTECH OY

Additional information:
CEO Kalevi Reijonen, FIT Biotech Oy Email: kalevi.reijonen@fitbiotech.com Phone: +358 40 843 5695

Certified Advisor: Translink Corporate Finance Oy, tel. +358 20 743 2790

FIT Biotech Oy in brief:
FIT Biotech Oy is a biotechnology company established in 1995, focusing on DNA vaccines and gene therapy. The company bases its products on its patented GTU ® (Gene Transport Unit) technology.

Through GTU technology, FIT Biotech develops DNA vaccines in order to both prevent and also treat various diseases. Identified application areas include HIV, tuberculosis (and other infectious diseases) as well as gene therapy (cancer, autoimmune diseases). Other application areas are under development.

FIT Biotech Oy is listed on NASDAQ First North (ticker: FITBIO). More information can be found at www.fitbiotech.com.

DISTRIBUTION:
NASDAQ OMX Helsinki
Principal media
www.fitbiotech.com

Back to list